CN104946680A - Recombinant vector for QC expression as well as preparation method, primers and genetically engineered bacteria of recombinant vector - Google Patents
Recombinant vector for QC expression as well as preparation method, primers and genetically engineered bacteria of recombinant vector Download PDFInfo
- Publication number
- CN104946680A CN104946680A CN201510318919.XA CN201510318919A CN104946680A CN 104946680 A CN104946680 A CN 104946680A CN 201510318919 A CN201510318919 A CN 201510318919A CN 104946680 A CN104946680 A CN 104946680A
- Authority
- CN
- China
- Prior art keywords
- expressing
- primer
- recombinant vectors
- preparation
- recombinant vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
The invention discloses a recombinant vector for QC expression as well as a preparation method, primers and genetically engineered bacteria of the recombinant vector. According to the preparation method, the PCR technology is adopted; an upstream primer SEQ ID NO.1 and a downstream primer SEQ ID NO.2 are utilized for defining a primer pair, and a QC33-361 gene segment is obtained through amplification of the primer pair; the recombinant vector for expressing the QC33-361 gene segment is obtained by connecting the QC33-361 gene segment onto an expression vector. When being transferred into a recipient cell, the recombinant vector can be utilized for synthesizing human glutaminylcyclase. The QC33-361 gene segment obtained through synthesis has the activity for remarkably catalyzing a glutaminylcyclase cyclization reaction in a substrate molecule, and can be utilized for the screening identification of a QC inhibitor, an agonist, an antagonist and the like, the research on QC related action mechanisms, the development of QC test related kits, the detection and diagnosis of QC high-expression related diseases, and the like.
Description
Technical field
The present invention relates to gene engineering technology field, particularly relate to a kind of for recombinant vectors of expressing QC and preparation method thereof, primer, genetic engineering bacterium.
Background technology
Glutaminyl cyclase (Glutaminylcyclase; QC; EC2.3.2.5) be that one can hold glutamine residue intramolecular cyclization reaction to generate the enzyme of Pyrrolidonecarboxylic acid (pGlu) by the N such as catalytic polypeptide, albumen, there is N such as changing albumen and hold chemical structure, regulate the important biomolecule functions such as activity, enhanced stability.
1963, QC found first in tropical plants papaya (Carica papaya) latex, and rear research confirms, QC all has distribution in plant, animal, microorganism.But in plant, the physiological function of QC is very not clear and definite, may have certain effect in plant defense pathogenic micro-organism process.QC enzyme kinetics behavior in plant, animal all meets Michaelis-Menton equation (Mechaelis-Menten), and has strict specificity to position, substrate N end L-glutaminate.Mammals QC has well-conserved, and without any sequence homology between papaya QC, and with bacterium aminopeptidase, there is significant sequence homology, therefore animal and plant QC has different evolutionary source.
Along with the development of human society age structure aging, senile dementia sickness rate raises rapidly.Alzheimer's disease (Alzheimer ' s disease, AD) be a kind of common nerve degenerative diseases, be the principal mode of senile dementia, epidemiology survey shows, and AD patient exceedes more than 65% of old dementia patients sum.A few days ago, AD sickness rate raises increasingly, has become the third-largest worldwide health problem being only second to cardiovascular and cerebrovascular diseases and tumour.
AD main clinic symptoms comprises Progressive symmetric erythrokeratodermia memory and cognition dysfunction etc., there is no specific treatment medicine at present.AD pathogenesis is complicated, through 100 years of researches, there has been proposed the hypothesis that some are different, as AD related protein entanglement and gathering, oxidative stress, biological metal ionic homeostasis is unbalance, mitochondrial function exhaustion etc., but exact mechanism does not understand.The Hyperphosphorylationof Tau albumen entanglement etc. of the AD pathological characteristics amyloid-beta precipitation that mainly brain neuroblastoma unit is outside and inside neurons.Amyloid-beta (A β) is the main component of senile plaque, and according to A β cascade theory, the excessive generation of A β and gathering, precipitation are considered to fall ill with AD and be in progress have direct relation.A β is that beta amyloid precursor protein (APP) is hydrolyzed gained fragment products, as A β 42/A β 40 through beta-secretase and gamma-secretase.The displays such as in vitro study, A β overexpression and gathering, precipitation directly can cause mitochondrial disorders, oxidative stress, nerve synapse transmission interruption, axonal transport interrupt, the impaired multiple AD related pathologies change such as to break of film integrality.
In recent years, jointly confirm with clinical study in multinomial body, be different from the senile plaque precipitation of Elderly people human brain, the main component of AD patient's brain senile plaque precipitation is not aβ protein, but the aβ protein of multiple variation, particularly N holds the pGlu-A β of 3-position glutamine residue molecule inner ring condensation, and comprise pGlu-A β 42/pGlu-A β 40, content is more than 50%.PGlu-A β has stronger stability, faster aggregate and precipitate speed, stronger neurotoxicity, and its generation is directly related with the generation of AD clinical symptom.This provides new clue for AD correlative study.Deeply showing further of correlative study, pGlu-A β is the product of QC effect.QC specificity overexpression is that AD falls ill early stage specific lesions, it is the crucial promoting factor of AD morbidity, development, Selective depression QC activity significantly can suppress the generation of pGlu-A β and the formation of senile plaque precipitation, and obviously improves the AD such as cognition, impaired memory function symptom.Therefore, QC is that AD pathology and causal innovation anti-AD drug research open new research direction.
QC zymoprotein is the necessary starting material of correlative study, and its product confrontation QC mechanism of action and inhibitor research have material impact.The acquisition of QC is prepared by the separation of QC active in natural goods and adopts genetic engineering technique preparation restructuring QC two kinds of methods to realize.The deficiencies such as extraction and separation method is lower by QC content in natural goods, extraction cost is high, lot stability is poor, loss of enzyme activity is serious, have larger restriction in applying.By contrast, genetic engineering technique preparation restructuring QC is the active QC preparation method of one being easier to realize.At present, have been reported and claim to express preparation restructuring QC by E.coli, but method exists certain defect, prepare that expression amount is low, enzymic activity is poor, step is various.Visible, a kind of newly, efficiently, fast can prepare the foundation of the method for high activity recombinant human QC, to QC Study on Correlative Mechanisms, the anti-AD new drug research of QC inhibitor class and the clinical diagnosis of QC abnormal expression relative disease etc., all there is very important scientific meaning and using value.
Summary of the invention
In view of above-mentioned the deficiencies in the prior art; the object of the present invention is to provide a kind of for recombinant vectors of expressing QC and preparation method thereof, primer, genetic engineering bacterium, provide a kind of efficiently, fast can prepare high reactivity human glutamine acyl group cyclase prepare approach.
Technical scheme of the present invention is as follows:
For expressing a preparation method for the recombinant vectors of QC, wherein, comprise the following steps:
Adopt round pcr, with upstream primer SEQ ID NO.1 and downstream primer SEQ ID NO.2 for primer pair, amplification obtains QC
33-361gene fragment; Wherein, upstream primer is 5 '-ACCTGGATCCGCTTCTGCTTGGCCGG-3 '; Downstream primer is 5 '-TATCCTCGAGTTACAGGTGCAGGTATTC-3 ';
By QC
33-361gene fragment is connected on expression vector, obtains for expressing QC
33-361recombinant vectors.
The preparation method of the described recombinant vectors for expressing QC, wherein, by QC
33-361the process that gene fragment is connected to expression vector comprises the following steps:
To carrier pET28a and pET32a, carry out EcoRI, XhoI double digestion respectively; Linearized vector two ends being existed equally EcoRI, XhoI site connects, and obtains improved pET32a carrier;
To QC
33-361gene fragment and improved pET32a carrier carry out BamHI and XhoI double digestion, two ends are existed equally the QC in BamHI, XhoI site
33-361gene fragment is connected with linearized vector.
For expressing a recombinant vectors of QC, wherein, QC is comprised in the described recombinant vectors for expressing QC
33-361gene fragment, shown in its nucleotide sequence SEQ ID NO.4.
The described recombinant vectors for expressing QC, wherein, adopts preparation method as above to prepare.
A kind of genetic engineering bacterium, wherein, containing as above for expressing the recombinant vectors of QC.
Described genetic engineering bacterium, wherein, the bacterial classification of described genetic engineering bacterium is bacillus coli DH 5 alpha or e. coli bl21 (DE3).
A kind of primer, wherein, described primer is used for amplification and obtains QC
33-361gene fragment, wherein, upstream primer is 5 '-ACCTGGATCCGCTTCTGCTTGGCCGG-3 '; Downstream primer is 5 '-TATCCTCGAGTTACAGGTGCAGGTATTC-3 '.
Beneficial effect: the invention provides a kind of recombinant vectors for expressing human glutamine acyl group cyclase, can be used for efficiently, fast prepare high activity recombinant human QC
33-361enzyme.By this vector in recipient cell, can be used for synthesis human glutamine acyl group cyclase.Synthesize the human glutamine acyl group cyclase QC obtained
33-361for having the activity of glutaminyl cyclase reaction in remarkable catalytic substrate molecule, can the intramolecular cyclisation of glutaminyl be held to generate the product of Pyrrolidonecarboxylic acid by efficient catalytic albumen (polypeptide) N.Synthesize the human glutamine acyl group cyclase QC obtained
33-361can be used for the screening discovery of QC inhibitor, agonist, antagonist etc., QC dependent interaction Mechanism Study, QC detect the exploitation of related kit, the checkout and diagnosis etc. of QC high expression level relative disease.
Accompanying drawing explanation
Fig. 1 is the structure schematic diagram of QC recombinant expression vector of the present invention.
Fig. 2 is QC in the embodiment of the present invention 1
33-361gene PCR amplification.
Fig. 3 is recombinant plasmid pET32a/QC in the embodiment of the present invention 1
33-361double digestion qualification result.
Fig. 4 is QC in the embodiment of the present invention 4
33-361sDS-PAGE analytical results in the expression and purification process of albumen.
Fig. 5 is gained QC in the embodiment of the present invention 4
33-361protein spectrum analyses and comparison result.
Fig. 6 is QC in the embodiment of the present invention 5
33-361enzymic activity test philosophy schematic diagram
Fig. 7 is QC in the embodiment of the present invention 5
33-361two matched curve figure reciprocal.
Embodiment
The invention provides a kind of recombinant vectors for expressing human glutamine acyl group cyclase and preparation method thereof, for making object of the present invention, technical scheme and effect clearly, clearly, the present invention is described in more detail below.Should be appreciated that specific embodiment described herein only in order to explain the present invention, be not intended to limit the present invention.
The present invention utilizes human glutamine acyl group cyclase QC
33-361it is a fragment of EC2.3.2.5 full-length proteins; the cDNA sequence of human pituitary QC is retrieved from GenBank; in conjunction with the feature of pET32a carrier; a pair Auele Specific Primer is designed with software Oligo; amplification obtains the gene order of QC enzyme, and is inserted on pET32a carrier, builds the recombinant vectors obtaining may be used for expressing human glutamine acyl group cyclase.Further, by this vector in recipient cell, can be used for synthesis human glutamine acyl group cyclase.Synthesize the human glutamine acyl group cyclase QC obtained
33-361for having the activity of glutaminyl cyclase reaction in remarkable catalytic substrate molecule, can the intramolecular cyclisation of glutaminyl be held to generate the product of Pyrrolidonecarboxylic acid by efficient catalytic albumen (polypeptide) N.Synthesize the human glutamine acyl group cyclase QC obtained
33-361can be used for the screening discovery of QC inhibitor, agonist, antagonist etc., QC dependent interaction Mechanism Study, QC detect the exploitation of related kit, the checkout and diagnosis etc. of QC high expression level relative disease.Wherein, described human glutamine acyl group cyclase QC
33-361aminoacid sequence be:
ASAWPEEKNYHQPAILNSSALRQIAEGTSISEMWQNDLQPLLIERYPGSPGSYAARQHIMQRIQRLQADWVLEIDTFLSQTPYGYRSFSNIISTLNPTAKRHLVLACHYDSKYFSHWNNRVFVGATDSAVPCAMMLELARALDKKLLSLKTVSDSKPDLSLQLIFFDGEEAFLHWSPQDSLYGSRHLAAKMASTPHPPGARGTSQLHGMDLLVLLDLIGAPNPTFPNFFPNSARWFERLQAIEHELHELGLLKDHSLEGRYFQNYSYGGVIQDDHIPFLRRGVPVLHLIPSPFPEVWHTMDDNEENLDESTIDNLNKILQVFVLEYLHL。
Particularly, provide a kind of recombinant vectors for expressing human glutamine acyl group cyclase and preparation method thereof in the present invention, wherein, the preparation method of the described recombinant vectors for expressing human glutamine acyl group cyclase, comprises the following steps:
1, adopt round pcr, with upstream primer SEQ ID NO.1 and downstream primer SEQ ID NO.2 for primer pair, amplification obtains QC
33-361gene fragment SEQ ID NO.4, QC
33-361the nucleotide sequence of gene fragment is as follows:
GCTTCTGCTTGGCCGGAAGAAAAAAACTACCACCAGCCGGCTATCCTGAACTCTTCTGCTCTGCGTCAGATCGCTGAAGGTACCTCTATCTCTGAAATGTGGCAGAACGACCTGCAGCCGCTGCTGATCGAACGTTACCCGGGTTCTCCGGGTTCTTACGCTGCTCGTCAGCACATCATGCAGCGTATCCAGCGTCTGCAGGCTGACTGGGTTCTGGAAATCGACACCTTCCTGTCTCAGACCCCGTACGGTTACCGTTCTTTCTCTAACATCATCTCTACCCTGAACCCGACCGCTAAACGTCACCTGGTTCTGGCTTGCCACTACGACTCTAAATACTTCTCTCACTGGAACAACCGTGTTTTCGTTGGTGCTACCGACTCTGCTGTTCCGTGCGCTATGATGCTGGAACTGGCTCGTGCTCTGGACAAAAAACTGCTGTCTCTGAAAACCGTTTCTGACTCTAAACCGGACCTGTCTCTGCAGCTGATCTTCTTCGACGGTGAAGAAGCGTTCCTGCACTGGTCTCCGCAGGACTCTCTGTACGGTTCTCGTCACCTGGCTGCTAAAATGGCTTCTACCCCGCACCCGCCGGGTGCTCGTGGTACCTCTCAGCTGCACGGTATGGACCTGCTGGTTCTGCTGGACCTGATCGGTGCTCCGAACCCGACCTTCCCGAACTTCTTCCCGAACTCTGCTCGTTGGTTCGAACGTCTGCAGGCTATCGAACACGAACTGCACGAACTGGGTCTGCTGAAAGACCACTCTCTGGAAGGTCGTTACTTCCAGAACTACTCTTACGGTGGTGTTATCCAGGACGACCACATCCCGTTCCTGCGTCGTGGTGTTCCGGTTCTGCACCTGATCCCGTCTCCGTTCCCGGAAGTTTGGCACACCATGGACGACAACGAAGAAAACCTGGACGAATCTACCATCGACAACCTGAACAAAATCCTGCAGGTTTTCGTTCTGGAATACCTGCACCTGTAA。
Wherein, upstream primer SEQ ID NO.1:5 '-ACCTGGATCCGCTTCTGCTTGGCCGG-3 '; Downstream primer SEQ ID NO.2:5 '-TATCCTCGAGTTACAGGTGCAGGTATTC-3 '.In upstream primer, " GGATCC " is nucleotide sequence corresponding to BamHI restriction enzyme site, and downstream primer " CTCGAG " is nucleotide sequence corresponding to XhoI restriction enzyme site.
2, respectively EcoRI, XhoI double digestion is carried out to existing carrier pET28a (28a-EcoRI-His6-PPE-BamHI-XhoI) and pET32a (32a-Trx-tag-s.tag-EcoRI-Hind-XhoI); Linearized vector two ends being existed equally EcoRI, XhoI connects, and obtain improved pET32a carrier (32a-Trx-tag-s.tag-EcoRI-His6-PPE-BamHI-XhoI), PPE is protease cutting site.
3, to QC
33-361gene fragment and improved pET32a carrier carry out BamHI and XhoI double digestion, two ends are existed equally the QC in BamHI, XhoI site
33-361gene fragment is connected with linearized vector, obtains pET32a/QC
33-361recombinant vectors.
A kind of recombinant vectors for expressing human glutamine acyl group cyclase provided in the present invention, described recombinant vectors is pET32a/QC
33-361recombinant vectors, adopt aforesaid method to prepare, the structure schematic diagram of described recombinant vectors as shown in Figure 1.A kind of genetic engineering bacterium also provided in the present invention, containing the above-mentioned recombinant vectors for expressing human glutamine acyl group cyclase in described genetic engineering bacterium.The bacterial classification of described genetic engineering bacterium can be bacillus coli DH 5 alpha or e. coli bl21 (DE3).
A kind of preparation method of glutaminyl cyclase is also provided in the present invention, comprises the following steps:
1, pET32a/QC is built
33-361recombinant vectors;
2, by pET32a/QC
33-361recombinant vectors is transformed in competent escherichia coli cell, obtains recombinant human QC expressing gene engineering bacteria.
3, recombination engineering bacteria is inoculated in the LB substratum containing resistance marker, abduction delivering.
4, after abduction delivering terminates, collect thalline, the broken thalline of bacteriolyze, high pressure, centrifugation, get supernatant liquor and carry out affinity chromatography and carry out purifying, collect containing QC
33-361fusion rotein.
5, to containing QC
33-361fusion rotein carry out PPE enzyme, desalination, molecular sieve column chromatography purifying, isolates QC
33-361albumen.
Wherein, described competent escherichia coli cell is bacillus coli DH 5 alpha or e. coli bl21 (DE3).The described LB substratum containing resistance marker is the LB substratum containing Cam (clarithromycin) resistance, or the LB substratum containing Amp (ammonia benzyl mycin) resistance.
Before conversion recombinant vectors, activation treatment can be carried out: by the actication of culture preserved, 37 DEG C are cultured to OD600 value in LB liquid medium is 0.6 ~ 0.8, makes bacterium liquid be cooled to 0 DEG C on ice to competent escherichia coli cell, collected by centrifugation thalline, with the 0.1mol/L CaCl of precooling
2solution prepares competent cell.
In step 2, detailed process can be, in competent escherichia coli cell, add pET32a/QC
33-361positive recombinant plasmid, leaves standstill 30min, 42 DEG C of water-soluble pot heat shock 60-70s on ice, leaves standstill 2min on ice, add appropriate LB liquid nutrient medium, 37 DEG C, 200rpm cultivates 50min, be applied on the LB solid plate with resistance marker, 37 DEG C of overnight incubation, obtain recombinant human QC expressing gene engineering bacteria.
In step 3, detailed process can be, picking recombination engineering bacteria list colony inoculation is to containing in 1 ‰ antibiotic LB liquid nutrient mediums, and 37 DEG C, 200rpm shaking table jolting about 10h, obtains seed culture fluid; Be inoculated into containing in 1 ‰ antibiotic LB nutrient solutions by seed culture fluid with the ratio of 1:200,37 DEG C, 200rpm, is cultured to OD600 value and reaches 0.6-0.8, induces 48 hours, 20 DEG C, 160rpm with the IPTG of 1mM (isopropylthiogalactoside).
In step 4, detailed process can be, the centrifugal 30min of bacterium liquid 8000rpm collects thalline, and use high pressure smudge cells instrument to split abundant cracking thalline, the centrifugal 50min of 25000rpm, supernatant liquor Ni ion affinity chromatography carries out separation and purification, collects containing QC
33-361fusion rotein.
In step 5, detailed process can be, with desalting column to the desalination of collection gained fusion rotein, carry out enzyme with PPE enzyme to fusion rotein to cut, cut mixed system with molecular sieve S-200Column to enzyme to carry out molecular sieve column chromatography and purify, carry out SDS-PAGE analysis, collect target protein QC
33-361.
Below by way of specific embodiment, the present invention will be further described.
Materials and methods:
People's pituitary body glutaminyl cyclase and QC
1-361gene is synthesized by Takara company.
Molecular cloning pET32a expression plasmid, Host Strains intestinal bacteria EcoliDH5 α, expressive host bacterium EcoliBL21DE3 etc. are our unit and preserve genetically engineered research material.
1 enzyme activity unit represents 25 DEG C, per minute internal consumption 1 micromole (μm ol) enzyme amount required for NADH, and unit is μM/min.
PrimeSTAR HS DNA Polymerase, Upstream primer, Downstream primer, dNTP Mixture equimolecular biological reagent are purchased from Takara company; The purchased from American NEB companies such as DNA restriction enzyme (BamHI, XhoI), T4DNA ligase; E.Z.N.A glue reclaims the purchased from American Omega company such as test kit, E.Z.N.A plasmid extraction kit; Albumen Marker, determination of protein concentration test kit etc. are purchased from TIANGEN Bioisystech Co., Ltd; The available from Sigma such as NADH, glutamate dehydrogenase, DMSO; N-Boc-QQ-2 is purchased from the biochemical company limited of Shanghai gill, and other common drugs, reagent, substratum etc. are purchased from Shanghai biotechnology company limited.
In the present invention, involved plasmid extraction, PCR, enzyme are cut, are linked the routine operation that conversion, abduction delivering, purification etc. are genetically engineered field
Embodiment 1 is containing the structure of people QC expression vector
According to QC enzyme number EC 2.3.2.5, retrieve the cDNA sequence of mankind QC from GenBank, according to pET32a carrier feature, with Oligo software design a pair Auele Specific Primer:
Upstream primer: 5-3:ACCTGGATCCGCTTCTGCTTGGCCGG;
Downstream primer: 5-3:TATCCTCGAGTTACAGGTGCAGGTATTC.
The restriction enzyme site of primer is cohesive terminus, and ensures except having corresponding restriction enzyme site in designed primer, and not containing the restriction enzyme site design primer in primer in the QC gene order of amplification, primer is synthesized by Takara company.With above-mentioned primer pair, carry out pcr amplification, goal gene (QC
33-361gene) pcr amplification result as shown in Figure 2, wherein, 1 is Marker, gene QC for the purpose of 2
33-361pCR primer.Adopt Omega E.Z.N.A glue to reclaim test kit and reclaim the goal gene (QC containing restriction enzyme site
33-361gene) fragment, BamHI-XhoI double digestion is carried out to goal gene fragment.
To existing carrier pET28a (28a-EcoRI-His6-PPE-BamHI-XhoI) and pET32a (32a-Trx-tag-s.tag-EcoRI-Hind-XhoI), carry out EcoRI, XhoI double digestion respectively; Linearized vector two ends being existed equally EcoRI, XhoI connects, and obtains improved pET32a carrier (32a-Trx-tag-s.tag-EcoRI-His6-PPE-BamHI-XhoI), wherein inserts PPE restriction enzyme site.
Also BamHI-XhoI double digestion is carried out to transformed pET32a carrier, obtains linearized vector, then two ends are existed equally the QC in BamHI, XhoI site
33-361object fragment is connected with linearized vector, obtains pET32a/QC
33-361positive recombinant plasmid.Carry out the qualification of BamHI-XhoI double digestion to recombinant plasmid, as shown in Figure 3, wherein, 1 is Marker to result, and 2 is the QC after EcoR Ι and Xho Ι double digestion
33-361gene fragment and plasmid fragments.
By pET32a/QC
33-361positive recombinant plasmid transformed, in Ecoli.DH5 α competent cell, is cultivated with Amp resistance LB solid medium, and PCR identifies primary dcreening operation positive colony.After positive colony is cultivated, extract plasmid, through Shanghai, raw work is identified correctly further, completes for the construction of recombinant vector of expressing human glutamine acyl group cyclase.
Embodiment 2 is recombinated the structure of QC expressing gene engineering bacteria
By the Ecoli.DH5 α actication of culture preserved, in LB liquid medium, 37 DEG C are cultured to OD600 value is 0.6 ~ 0.8, makes bacterium liquid be cooled to 0 DEG C on ice, collected by centrifugation thalline, with the 0.1mol/L CaCl of precooling
2solution prepares competent cell.Then, in competent cell, pET32a/QC is added
33-361positive recombinant plasmid, leave standstill 30min on ice, 42 DEG C of water-soluble pot heat shock 60-70s, leave standstill 2min on ice, add 700 μ l LB liquid nutrient mediums, 37 DEG C, 188 × g cultivates 50min, is applied on the LB solid plate with Amp resistance, 37 DEG C of overnight incubation, build recombinant human QC expressing gene engineering bacteria, can directly carry out next step abduction delivering operation.
The efficiently purifying preparation of embodiment 3 recombinant human QC
On the LB solid plate with ammonia benzyl (Amp) resistance marker, the positive single bacterium colony of picking, is inoculated in the 5ml LB liquid medium containing 1 ‰ Amp, 37 DEG C, 188 × g jolting about 10h, and expand by 1:200 and connect, 37 DEG C are cultured to OD
600value reaches 0.6-0.8, adds the IPTG of 1mM, 20 DEG C, 150 × g abduction delivering two days; Can regularly sample with the expression amount of SDS-PAGE analysis purposes albumen.
Abduction delivering terminates, and the centrifugal 30min of bacterium liquid 7530 × g collects thalline, and use the abundant cracking thalline of high pressure smudge cells instrument, the centrifugal 50min of 35000 × g, cellular lysate supernatant liquor carries out Ni affinitive layer purification.Get 250ul Ni filler in 1.5mlEP pipe, centrifugal, abandoning supernatant, then balances pillar 2 times with lysate, supernatant discarded, the supernatant liquor of cellular lysate is transferred to the EP pipe of 15ml, Ni-bead is transferred in the protein liquid of 15ml, be placed on refrigerator rocker and shake 45min, 800-900rpm, 4 DEG C, 2min, supernatant discarded; With 20mM imidazole elution by Ni filler-protein delivery in 1.5ml EP pipe, and wash three times, then wash two times with 40mM imidazole elution, finally wash with 250mM imidazole elution, collect the fusion rotein containing target protein.
Preparation 150mM NaCl, 50mM Tris damping fluid, with desalting column to the desalination of collection gained fusion rotein, PPE:QC=1:100 (concentration of PPE is 2mg/ml) adds PPE enzyme by volume, 4 DEG C of enzymes cut through night, cut rear mixed system and carry out molecular sieve column chromatography and purify, and carry out 15%SDS-PAGE analysis with molecular sieve S-200Column to enzyme, collect target protein, Coomassie brilliant blue G250 solution surveys protein concentration, protein concentrate, directly use or frozen for subsequent use in-80 DEG C.Gained QC recombinant protein is identified as people QC, so far successful expression QC through MS.
QC
33-361as shown in Figure 4, wherein, band 1 is Marker to SDS-PAGE analytical results in the expression and purification process of albumen, and band 2 is the cellular lysate liquid supernatant liquor of IPTG abduction delivering 48h, and band 3 is the pET32a/QC after Ni affinitive layer purification
33-361warm albumen, band 4 cuts the mixed system of 12-16h for PPE enzyme, and band 5 is molecular sieve column chromatography purification QC
33-361.
Gained QC
33-361as shown in Figure 5, retrieve expressed albumen is Human QC to protein spectrum analyses and comparison result really.
Embodiment 4 recombinant human QC enzymatic activity is tested
Now join TFA in proportion: tri isopropyl silane: phenol: water=88:5:5:2 mixed solution; prepare fresh QC substrate Gln-Gln for enzyme test alive to N-Boc-Gln (Trt)-Gln (Trt) deprotection, QC enzymic activity test philosophy schematic diagram as shown in Figure 6.Enzyme is lived in testing and is carried out in 96 hole enzyme plates, adopt 200ul pH8.0Tris buffer system: 0.3mM NADH, different concns substrate Gln-Gln (0mM, 0.12mM, 0.24mM, 0.96mM, 1.2mM, 1.92mM, 2.4mM, 3.84mM), 14mM α-ketoglutaric acid, 30U/ml glutamate dehydrogenase, 50mM Tris, pH8.0 damping fluid, finally adds the QC of different concns
33-361(0.028 μM, 0.056 μM, 0.11 μM, 0.14 μM, 0.28 μM), with the absorption value change in 340nm wavelength place 15min of NADH during microplate reader detection of dynamic 25 DEG C, carries out a data gathering every 30s.Test result as shown in Figure 7, according to test result, analyzes Vmax=333.33mM/min, Km=0.86mM, Kcat=12.68s of recombinant human QC with Michaelis-Menton equation, two reciprocal equation
-1.
Should be understood that, application of the present invention is not limited to above-mentioned citing, for those of ordinary skills, can be improved according to the above description or convert, and all these improve and convert the protection domain that all should belong to claims of the present invention.
Claims (7)
1. for expressing a preparation method for the recombinant vectors of QC, it is characterized in that, comprising the following steps:
Adopt round pcr, with upstream primer SEQ ID NO.1 and downstream primer SEQ ID NO.2 for primer pair, amplification obtains QC
33-361gene fragment; Wherein, upstream primer is 5 '-ACCTGGATCCGCTTCTGCTTGGCCGG-3 '; Downstream primer is 5 '-TATCCTCGAGTTACAGGTGCAGGTATTC-3 ';
By QC
33-361gene fragment is connected on expression vector, obtains for expressing QC
33-361recombinant vectors.
2. the preparation method of the recombinant vectors for expressing QC according to claim 1, is characterized in that, by QC
33-361the process that gene fragment is connected to expression vector comprises the following steps:
To carrier pET28a and pET32a, carry out EcoRI, XhoI double digestion respectively; Linearized vector two ends being existed equally EcoRI, XhoI site connects, and obtains improved pET32a carrier;
To QC
33-361gene fragment and improved pET32a carrier carry out BamHI and XhoI double digestion, two ends are existed equally the QC in BamHI, XhoI site
33-361gene fragment is connected with linearized vector.
3. for expressing a recombinant vectors of QC, it is characterized in that, in the described recombinant vectors for expressing QC, comprising QC
33-361gene fragment, shown in its nucleotide sequence SEQ ID NO.4.
4. the recombinant vectors for expressing QC according to claim 3, is characterized in that, adopts preparation method as claimed in claim 1 or 2 to prepare.
5. a genetic engineering bacterium, is characterized in that, containing, for example the recombinant vectors for expressing QC according to claim 3.
6. genetic engineering bacterium according to claim 5, is characterized in that, the bacterial classification of described genetic engineering bacterium is bacillus coli DH 5 alpha or e. coli bl21 (DE3).
7. a primer, is characterized in that, described primer is used for amplification and obtains QC
33-361gene fragment, wherein, upstream primer is 5 '-ACCTGGATCCGCTTCTGCTTGGCCGG-3 '; Downstream primer is 5 '-TATCCTCGAGTTACAGGTGCAGGTATTC-3 '.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510318919.XA CN104946680A (en) | 2015-06-11 | 2015-06-11 | Recombinant vector for QC expression as well as preparation method, primers and genetically engineered bacteria of recombinant vector |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510318919.XA CN104946680A (en) | 2015-06-11 | 2015-06-11 | Recombinant vector for QC expression as well as preparation method, primers and genetically engineered bacteria of recombinant vector |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104946680A true CN104946680A (en) | 2015-09-30 |
Family
ID=54161743
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510318919.XA Pending CN104946680A (en) | 2015-06-11 | 2015-06-11 | Recombinant vector for QC expression as well as preparation method, primers and genetically engineered bacteria of recombinant vector |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104946680A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102112880A (en) * | 2008-07-31 | 2011-06-29 | 前体生物药物股份公司 | Glutaminyl cyclase as a diagnostic / prognostic indicator for neurodegenerative diseases |
-
2015
- 2015-06-11 CN CN201510318919.XA patent/CN104946680A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102112880A (en) * | 2008-07-31 | 2011-06-29 | 前体生物药物股份公司 | Glutaminyl cyclase as a diagnostic / prognostic indicator for neurodegenerative diseases |
| CN103983787A (en) * | 2008-07-31 | 2014-08-13 | 前体生物药物股份公司 | Glutaminyl cyclase as a diagnostic/prognostic indicator for neurodegenerative diseases |
Non-Patent Citations (2)
| Title |
|---|
| KAI-FA HUANG,ET AL: "Crystal structures of human glutaminyl cyclase, an enzyme responsible for protein N-terminal pyroglutamate formation", 《PNSA》 * |
| NCBI: "Chain A,Crystal Structure of Human Glutaminyl Cyclase At Ph 6.5", 《NCBI》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Suda et al. | Evidence for a novel Chlorella virus-encoded alginate lyase | |
| Zhao et al. | Comparative genomics reveal pathogenicity‐related loci in Pseudomonas syringae pv. actinidiae biovar 3 | |
| CN107287171B (en) | Enzyme and application thereof | |
| CN102618552A (en) | Productive technology of recombined exenatide | |
| CN106939315B (en) | Preparation method and application of oxalate decarboxylase | |
| CN113174398B (en) | Expression cassette for recombinant expression of echinocandin B deacylase and application | |
| WO2024008204A1 (en) | Use of mmpi in preparation of trypsin inhibitor | |
| CN108570107B (en) | Expansin and xylanase fusion protein, and coding gene and application thereof | |
| CN110591992B (en) | Genetically engineered bacterium capable of efficiently degrading tetracycline antibiotics and construction and application thereof | |
| Yang et al. | A small periplasmic protein essential for Cytophaga hutchinsonii cellulose digestion | |
| CN108929883B (en) | Application of spoIII E gene related to sporulation in influencing growth of strain and producing enzyme | |
| CN104946680A (en) | Recombinant vector for QC expression as well as preparation method, primers and genetically engineered bacteria of recombinant vector | |
| CN104946609A (en) | Preparation method for glutaminyl cyclase | |
| EP1523548B1 (en) | Polynucleotide sequences encoding alkaline a-galactosidases and methods of using same | |
| CN104928308B (en) | Thrombolysis enzyme gene and recombinant expression carrier, recombinant bacterium and application containing the gene | |
| Yu et al. | Draft genome sequence, disease-resistance genes, and phenotype of a Paenibacillus terrae strain (NK3-4) with the potential to control plant diseases | |
| JP2004313074A (en) | NEW alpha-1,2-MANNOSIDASE AND GENE ENCODING THE SAME, AND METHOD FOR PRODUCING alpha-MANNOSYL SUCCHARIDE COMPOUND USING THE ENZYME | |
| Mori et al. | A heterodimeric hyaluronate lyase secreted by the activated sludge bacterium Haliscomenobacter hydrossis | |
| WO2021258637A1 (en) | Trypsin-like serine protease gene, encoded protein and application | |
| Abady et al. | Molecular cloning, heterologous expression, and in silico sequence analysis of Enterobacter GH19 class I chitinase (chiRAM gene) | |
| CN113088505B (en) | Application of polysaccharide lyase coding gene 04147 in preparation of recombinant peach gum polysaccharide hydrolase | |
| CN117660413B (en) | Endolysin Lys009, engineering modification and application thereof | |
| CN117586991B (en) | Beta-N-acetaminophen hexosaminidase FlaNag2353 and application thereof | |
| JP5354710B2 (en) | Highly active catalase-producing microorganism and use thereof | |
| Affandi et al. | Interactomics: Development of an efficient and improved Agrobacterium tumefaciens-mediated transformation method for transient expression of heterologous protein in recalcitrant plant tissues in planta |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150930 |
|
| RJ01 | Rejection of invention patent application after publication |